Petros Pharmaceuticals reported $784K in operational cash burn in Q1 2026, leaving approximately $4.35 million in cash and raising substantial doubt about the company's ability to continue as a going concern without additional capital. The company has shifted its business model from pharmaceutical manufacturing and distribution to developing a dual-component technology platform—combining SaaS for pharmaceutical partners and Software as a Medical Device (SaMD) for consumers—to streamline and commercialize Rx-to-OTC switches, especially leveraging the FDA's new ACNU regulatory framework. Despite promising technology and potential first-mover advantages, Petros faces significant execution risk, intense competition from established pharma and tech companies, and urgent capital requirements.